Inoperable advanced/recurrence Gastric Cancer or Colorectal Cancer
Conditions
Interventions
Group A: * 1st course : Conventional therapy (Palonosetron 0.75 mg i.v. on 1st day + Dexamathasone 9.9 mg i.v. on 1st day, 8 mg p.o. on 2nd day and 3rd day) * 2nd course : Conventional therapy (Palo
Sponsors
Osaka Medical College Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patient who has Gastric Cancer or Colorectal Cancer receiving FOLFILI, CPT-11 monotherapy, FOLFOX or XELOX regimen (2) Performance Status (ECOG)=0-2
Exclusion criteria
Exclusion criteria: (1) Patient who has severe liver failure or renal failure (2) Patient who has vomited or provoked nausea in the 24 hours prior to start of chemotherapy (3) Patient who has a factor that induces nausea or vomitting except chemotherapy (brain tumor, obstruction of gastrointestinal tract, active peptic ulcer, brain metastasis et al) (4) Patient who is considered inappropriate as a target patient by a physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| * Frequency of vomiting * Severity of nausea | — |
Secondary
| Measure | Time frame |
|---|---|
| * Grading of appetite * Used amount of per-request medication | — |
Countries
Japan
Contacts
Public ContactMasahiro Goto
Osaka Medical College Hospital Chemotherapy Cancter
Outcome results
None listed